Dr. Reddy’s can supply leftover Olymviq stock to government hospitals after 30-day window
Delhi High Court, Dr. It allowed Reddy’s Laboratories to supply the remaining stock of semaglutide drug Olymviq to government hospitals after the 30-day stock clearance period expires.
Justice Jyoti Singh officially recorded the agreement between them. Dr. The Indian pharmaceutical company will stop using the Olymviq name and switch to a new brand, Olymra, Reddy said on Friday.
The commitment applies not only to: Dr. Reddy’s, as well as its directors, subsidiaries and related entities, all of whom will cease the manufacture, sale, supply, distribution, promotion and any commercial use of the disputed trademark, both online and offline.
According to the agreement, Dr. Reddy’s was allowed to sell existing Olymviq stocks on the market for 30 days. Unsold stocks can then be supplied to public hospitals in the presence of a representative of Novo Nordisk. The Mint reported on March 29 Dr. He said Reddy’s will get 30 days to clear its inventory after undertaking before the court that it will change its brand name and withdraw its trademark applications.
It had already been examined and reported in his written order dated March 27. MintThe court stated that the company would withdraw the pending trademark applications for Olymviq from the Trademark Registry so that no further claims would be made to the disputed trademark.
The court explained that the limited window for clearing stocks was given in the public interest, especially because the drug is used by diabetic patients. The company had previously denied Novo Nordisk’s request to destroy or repackage inventory, stating that destroying already produced stock could harm patient access.
The court also expressed reservations about relabeling, questioning its commercial viability.
Dr. Reddy’s and Novo Nordisk, Dr. He did not immediately respond to emails from Reddy’s. Mint looking for comments.
similar name
The dispute stems from a trademark infringement lawsuit filed by Novo Nordisk, which alleges that Olymviq is deceptively similar to Ozempic, the well-known trademark used for the blockbuster drug semaglutide.
Semaglutide, a widely used treatment for type 2 diabetes and weight control, is marketed worldwide by Novo Nordisk under the brand names Ozempic, Wegovy and Rybelsus. The drug went off patent in India on March 20 and Dr. It has triggered a wave of lower-cost generic launches by domestic pharmaceutical companies, including Reddy’s.
Novo argued that Ozempic was an invented and well-known brand with global sales exceeding $63 billion over the past five years, and that using similar names in the same therapeutic segment could dilute the brand and create confusion among patients and prescribers.
Dr. Reddy filed trademark applications for Olymviq in July 2025 and again in March 2026, and has been in a separate legal dispute with Novo Nordisk since May 2025 over alleged infringement of the semaglutide patent.
